Shares of Teva Pharmaceutical Industries surged 45% after strong earnings, leading investors to consider two other drug makers, Pfizer and Merck. Teva specializes in generic drugs, while Pfizer and Merck focus on branded originals, facing patent cliffs. Teva’s debt, losses, and lack of dividends raise concerns, unlike Pfizer and Merck, which have strong financials and consistently turn profits. Pfizer and Merck are investing in new drugs to replace expiring patents, making them attractive long-term investments with lower price-to-earnings ratios compared to Teva. Investors may choose stability over short-term gains with Pfizer or Merck.

Read more at Yahoo Finance: Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?